Nizubaglustat in GM2 Gangliosidosis

About this episode

Kyle Landskroner and Jagdeep S. Walia discuss the effects of nizubaglustat in a mouse model of GM2 gangliosidosis.

In this episode, Kyle Landskroner and Jagdeep S. Walia talk about their paper on nizubaglustat in a mouse model of GM2 gangliosidosis. They explore how this brain-penetrant dual GCS/NLGase inhibitor improved survival, motor function, and neuroinflammatory markers in Sandhoff disease mice, and what that could mean for future therapies in GM2 disease. Therapeutic Effects of Nizubaglustat in a Mouse Model of GM2 Gangliosidosis Kyle Landskroner, Kshitiz Singh, Melissa Mitchell, Jagdeep S. Walia https://doi.org/10.1002/jimd.70130

People in this episode

Guests: Kyle Landskroner, Jagdeep S. Walia

Topics covered

• GM2 Gangliosidosis
• Nizubaglustat
• neuroinflammation
• motor function
• therapeutic effects

Keywords

• nizubaglustat
• GM2 gangliosidosis
• Sandhoff disease
• motor function
• neuroinflammatory markers

Mentioned in this episode

Organizations: Journal of Inherited Metabolic Disease

Books & works: Therapeutic Effects of Nizubaglustat in a Mouse Model of GM2 Gangliosidosis

More episodes of JIMD Podcasts

• High Glycine, Different Diagnoses · June 9, 2026 · 24 min
• IMD Research Round-Up: Homocystinuria · June 2, 2026 · 42 min
• Revisiting D-Bifunctional Protein Deficiency · May 26, 2026 · 20 min
• Metabolic Mysteries: Two adult siblings with liver disease and haematological abnormalities · May 19, 2026 · 6 min
• The Grey Zone in ABCD1 Variant Classification · May 12, 2026 · 33 min
• Metabolic Mysteries: A 57-year-old man with vomiting and worsening confusion · May 5, 2026 · 4 min